Gut/Brain Inflammation Link in HIV Wins $5.8M NIH Grant

Researchers at Oregon Health & Science University have landed a five-year, $5.8 million grant from the National Institute of Mental Health, part of the National Institutes of Health, to pursue one of the most stubborn mysteries in modern HIV medicine: why so many people whose virus is fully suppressed by antiretroviral therapy still experience cognitive decline that resembles accelerated aging. The team, co-led by Afam Okoye and Jacob Estes of OHSU’s Vaccine & Gene Therapy Institute, suspects the answer may lie far from the brain itself — in the damaged immune landscape of the gastrointestinal tract. Their central hypothesis is that lasting injury to gut-resident immune cells, inflicted at the moment of initial HIV infection and never fully repaired, sustains a low-grade inflammatory signal that travels to the central nervous system and quietly erodes neurological health over decades.

The clinical paradox driving the research is well documented. Combination antiretroviral therapy has transformed HIV from a nearly uniform death sentence into a manageable chronic condition, suppressing viral replication to undetectable levels in the blood for millions of people worldwide. Yet epidemiological studies consistently show that people living with HIV face elevated rates of neurocognitive disorders, a spectrum of impairment in memory, attention, and executive function that can resemble the earliest stages of dementia. Okoye framed the problem bluntly in the university’s announcement: even with very successful viral suppression, people living with HIV develop neurocognitive disorders similar to what happens with aging. If a dynamic relationship between gut inflammation and the brain can be demonstrated, he argued, the work could point toward new treatments designed specifically to reduce neuroinflammation.

The biological rationale for looking at the gut rests on a substantial body of immunology. The gastrointestinal tract harbors the largest concentration of immune cells in the human body, and it is also the site where HIV inflicts some of its earliest and most severe damage. Within weeks of infection, the virus devastates CD4-positive T cells concentrated in gut-associated lymphoid tissue, the mucosal immune network that lines the intestines and normally keeps microbial communities in check. Even when antiretroviral drugs later drive the virus into remission, this mucosal architecture often fails to fully recover, leaving the intestinal barrier weakened and the local immune environment chronically activated. Microbial products that would ordinarily remain confined to the gut lumen can then translocate into circulation, providing a plausible, persistent trigger for systemic inflammation — and, by extension, for inflammatory signaling that reaches the brain.

Evidence linking intestinal inflammation to neurological disease extends well beyond HIV. People with inflammatory bowel disease carry an increased risk of developing Parkinson’s disease and Alzheimer’s disease, an association that has fueled a decade of research into the so-called gut-brain axis. Immune cells and inflammatory mediators can influence the central nervous system through several routes, including signaling across the blood-brain barrier, communication along the vagus nerve, and the trafficking of activated immune cells from the periphery into brain tissue. In people with HIV, this crosstalk appears to be amplified: the problem of neurocognitive impairment disproportionately affects this population compared with uninfected peers of similar age, suggesting that HIV-related gut damage may act as a chronic accelerant of neuroinflammation that would otherwise remain dormant.

Studying this process directly in living humans, however, is extraordinarily difficult. The brain tissue where neuroinflammation unfolds is inaccessible to routine sampling, and the immune dynamics of the gut are hard to track longitudinally in patients already managing complex treatment regimens. Okoye, who also holds an appointment in the Division of Pathobiology and Immunology at OHSU’s Oregon National Primate Research Center, acknowledged these obstacles in the announcement. Neuroinflammation in people with HIV is very hard to study, he said, describing the work as challenging, high risk, but also high reward. The program’s design reflects that reality: it will pair nonhuman primate models, in which disease progression can be monitored in fine detail over time, with human autopsy tissues that reveal how the same processes played out in real patients.

Nonhuman primates infected with simian immunodeficiency virus, the primate counterpart of HIV, have long served as the most faithful animal model of human HIV disease, reproducing the pattern of acute gut immune destruction, persistent viral reservoirs, and chronic immune activation that defines the human infection. At the Oregon National Primate Research Center, researchers can examine the same animal’s gut and nervous system at multiple time points, correlating measures of mucosal inflammation with markers of immune activation in the brain. By aligning those longitudinal findings with pathological examination of human autopsy tissue — work that will involve pathologists at OHSU and infectious disease specialists at the NIH — the team hopes to characterize precisely how inflammation in the gut is linked to brain function, moving the field beyond correlation and toward a mechanistic account of the gut-brain pathway in HIV.

The therapeutic ambition underlying the grant is as important as its diagnostic one. Chronic inflammation is a double-edged sword: it contributes to tissue damage and disease progression, yet it remains an essential weapon of the immune system against infection. Any intervention that simply extinguishes inflammatory signaling wholesale would leave patients vulnerable to opportunistic infections and malignancies. Estes, professor and director of the Vaccine & Gene Therapy Institute, emphasized this balance in the announcement. Inflammation in and of itself is not bad, he said, noting that it is part of the immune system’s response to mediate infection. The goal, he explained, is to identify precision targets that would limit the pathology harming brain function without completely shutting off the immune system’s ability to do what it needs to do to promote health.

Such precision targeting, if the research succeeds, could reshape care for a population that is aging rapidly. Thanks to the success of antiretroviral therapy, the majority of people living with HIV in high-income countries are now middle-aged or older, and their lifetime exposure to residual immune activation is being recognized as a contributor to age-associated conditions ranging from cardiovascular disease to frailty. A therapy that selectively damps the harmful component of gut-driven inflammation could, in principle, preserve cognitive function not only in people with HIV but potentially in older adults more broadly, since many of the same inflammatory pathways are implicated in neurodegeneration across the general population. The OHSU team’s findings could therefore resonate far beyond virology, touching gerontology, neurology, and gastroenterology simultaneously.

The award, designated R01MH146623 by the National Institute of Mental Health, reflects a growing federal investment in understanding how systemic immune states shape the brain in chronic viral infection. It also underscores the distinctive infrastructure that Oregon brings to the problem: a vaccine and gene therapy institute focused on persistent pathogens, a national primate research center with decades of experience in lentiviral models, and clinical pathology expertise capable of translating animal findings into human evidence. As the five-year program unfolds, the researchers will be watching for a clear signal — that the state of the gut immune system predicts, and perhaps drives, the inflammatory fingerprint in the brain. If that signal emerges, the long-standing separation between gastroenterology and neurology in HIV care may begin to close, opening a new front in the effort to ensure that people living with HIV not only survive the virus but keep their minds intact for the decades of life that antiretroviral therapy has made possible.

Subject of Research: The role of gastrointestinal tract immune damage and inflammation in neurocognitive impairment among people living with HIV.

Article Title: Oregon researchers explore link between gut, brain health for people with HIV

Article References: Oregon researchers explore link between gut, brain health for people with HIV. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: HIV, neuroinflammation, gut-brain axis, OHSU, NIH grant, antiretroviral therapy, nonhuman primates, cognitive decline, inflammatory bowel disease, immune activation, neurocognitive disorders, Oregon National Primate Research Center